Effect of vascular endothelial growth factor-induced angiogenesis on TRAM flap harvesting after abdominoplasty.
In this study, the effect of intramuscular injection of human vascular endothelial growth factor (hVEGF) on neovascularization following abdominoplasty was investigated. Twenty-four Sprague-Dawley rats were divided into four groups (n = 6). Two control groups and two experimental groups were established. Abdominoplasty was performed in all rats, with division of all the perforator vessels. In the control groups, normal saline was injected into the rectus abdominis muscle, and in the experimental groups, 100 microg of VEGF and normal saline were injected into the rectus muscle. A transverse rectus abdominis musculocutaneous (TRAM) flap was harvested on day 20 and day 40 in both the control and experimental groups. The range of viability of the TRAM flap was, respectively, 0 to 20 percent (mean, 6.7 percent) and 0 to 25 percent (mean, 14.2 percent) in both short-term and long-term control groups (no VEGF injected). The study (VEGF) group demonstrated a viability of 50 to 80 percent (mean, 70 percent) for the short-term group and 50 to 85 percent (mean, 72.5 percent) in the long-term group. No wound infection was documented, and there were no deaths during the study period. There was no statistically significant difference between the short-term and long-term divisions of the groups (p < 0.01); however, significant differences were observed between the control and experimental groups (p < 0.01). The authors concluded that VEGF injection after abdominoplasty improved the percentage of TRAM flap viability. This method of delay/revascularization could be used for the difficult problem of flap viability following abdominoplasty and for high-risk patients.
Seify
Hisham
H
Division of Plastic, Reconstructive, and Maxillofacial Surgery, Emory University School of Medicine, 550 Peachtree Street, Atlanta, GA 30308, USA.
Bulky
Ufuk
U
Jones
Glyn
G
D034861:Abdominal Wall / Q000601:surgery*; D000818:Animals; D016228:Endothelial Growth Factors / Q000494:pharmacology*; D036341:Intercellular Signaling Peptides and Proteins / Q000494:pharmacology*; D008222:Lymphokines / Q000494:pharmacology*; D008297:Male; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D020033:Protein Isoforms / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013524:Surgical Flaps / Q000098:blood supply*; D020858:Tissue and Organ Harvesting; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D020033:Protein Isoforms; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors